Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PRO-230 in Healthy Volunteers
NCT05481489Phase 1Withdrawn
- Sponsor
- Laboratorios Sophia
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Myopine in myopia, sponsored by Laboratorios Sophia. Primary endpoints: Incidence of unexpected adverse events at Day 21 and Incidence of photophobia at Day 21. Planned start Feb 2023; status: withdrawn.
02
Drugs
Myopine
03
Conditions
myopia
Beyond the preview
Go deeper on NCT05481489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481489.